Quantum Genomics

Beleggen in aandelen beurzen Frankfurt DAX, Londen FTSE 100, Parijs CAC40

Stofke
Premiummember
Premiummember
Berichten: 796
Lid geworden op: 13 okt 2017 16:18
waarderingen: 445
Contacteer:

Re: Quantum Genomics

Bericht door Stofke » 02 aug 2019 16:23

Vanmorgen publiceerde een invloedrijke persoonlijkheid uit de aandelenmarkt een analyse van de titel Quantum Genomics. Zoals gebruikelijk stortte de titel Quantum Genomics na zijn technische analyse in. Het is jammer om technisch te spreken zonder de grondbeginselen van een bedrijf te kennen. Fundamentals hebben altijd voorrang op technische analyse. Deze zelfde specialisten, mediums van technische analyse, zeggen meestal alles en hun tegendeel in de tijd van enige tijd. De invloed en het aantal aandeelhouders dat deze analyses volgt, kan veel schade aanrichten, het bewijs bij de opening, de titel stortte bijna € 4,80 in -6%! Beleggers zullen moeten kiezen tussen een onbegrijpelijke negatieve analyse en de unieke en uitzonderlijke fundamenten van de enige biotech ter wereld die een revolutie teweegbrengt in de behandeling van hart- en vaatziekten met een revolutionair proces op basis van 25 jaar onderzoek!

Bovendien, welke interesse is er om dergelijke analyses te publiceren?

Laten we teruggaan naar de basisprincipes:

Quantum Genomics is zeker een van de weinige Franse biotechbedrijven die profiteren van zo'n groot opwaarts potentieel. Het managementteam van de Parijse biotech bereidt een partnerschap voor dat niet lang zal worden aangekondigd. Zoals de heer Milon onlangs heeft uitgelegd, wordt een partnerschap slechts eenmaal ondertekend, dus het is noodzakelijk om het best mogelijke partnerschap te ondertekenen ten behoeve van patiënten, aandeelhouders en de samenleving.

Ter herinnering, Quantum Genomics heeft uitstekende resultaten gepubliceerd van fase 2b NEW-HOPE bij hoge bloeddruk, uitstekende resultaten van een enkelvoudig dosisgeneesmiddel bij hoge bloeddruk, veelbelovende resultaten voor QGC006 die de activiteit remden van aminopeptidase Een 10-voudige groter dan die van Firibastat en bevestigde de werkzaamheid van QGC006 als een antihypertensivum.

De uitstekende resultaten van fase 2b NEW-HOPE in hypertensie zijn gepubliceerd in de meest prestigieuze wetenschappelijke tijdschriften ter wereld, VS, Europa, Azië en deze resultaten zijn superieur aan die van Idorsia, de enige concurrent van Quantum Genomics heeft een $ 230 miljoen samenwerking getekend met Janssen, een dochteronderneming van Johnson & Johnson.

Als we deze week het voorbeeld nemen van Genomic Vision dat een eenvoudige overeenkomst met Sanofi heeft ondertekend, zonder enige details van deze overeenkomst, is de aandelenkoers tijdens de sessie met + 275% gestegen!

Dit suggereert het mogelijke voordeel van Quantum Genomics in het geval van een aankondiging van een partnerschap met een farmaceutisch bedrijf van de eerste bestelling.

De fundamenten van Quantum Genomics zijn uniek en revolutionair.

Lionel Seguard, de oprichter van Quantum Genomics heeft niet toevallig gekozen, Jean-Philippe Milon, voormalig wereldpresident van fusies en overnames bij BAYER. Zijn ervaring zal hem in staat stellen om de op handen zijnde missie te concretiseren.

Ruedelabiotechnologie hernieuwt zijn steun aan Jean-Philippe Milon, Marc Karako, Fabrice Balavoine en professor Bruno Besse. Dit leiderschapsteam is opwindend en worstelt, laten we niet vergeten om levens te redden.

Bron: https://ruedelabiotechnologie.wordpress ... ssion=true



powered by Surfing Waves

Stofke
Premiummember
Premiummember
Berichten: 796
Lid geworden op: 13 okt 2017 16:18
waarderingen: 445
Contacteer:

Re: Quantum Genomics

Bericht door Stofke » 04 aug 2019 20:19

Quantum Genomics : Vidéo explicative de la molécule QGC001.

https://ruedelabiotechnologie.wordpress ... ssion=true

Stofke
Premiummember
Premiummember
Berichten: 796
Lid geworden op: 13 okt 2017 16:18
waarderingen: 445
Contacteer:

Re: Quantum Genomics

Bericht door Stofke » 04 aug 2019 20:35

Advances in Medicine Cause New, Groundbreaking Drug by Quantum Genomics (QNNTF) to Help With Chronic Hypertension.

NEW YORK, NY / ACCESSWIRE / August 2, 2019 / Quantum Genomics (QNNTF)(Euronext Paris:ALQGC) are the creators of Firibastat, a first-in-class brain aminopeptidase inhibitor (BAPAI) that could potentially treat treatment-resistant hypertension by acting in the brain to interfere with the renin-angiotensin system.

It is estimated that there are around 150 million people worldwide that are affected by treatment-resistant hypertension, resulting in almost 10 million deaths per year from complications due to high blood pressure. With such a high number of people dealing with this chronic condition (around 1.1 billion people). For those with treatment-resistant hypertension, they can be more susceptible to complications associated with hypertension such as heart failure, coronary artery disease, stroke, kidney disease and peripheral artery disease.

Standard treatments for hypertension include extensive lifestyle changes to address potential factors that may have contributed to the disease and multi-drug regimens, based on the preference of the treating doctor.

Firibastat works by crossing the blood-brain barrier and modulating the brain renin-angiotensin system (RAS). RAS is a hormone system that controls blood pressure in part by modulating dilation and constriction of the blood vessels throughout the body, there is a RAS system in the brain, and at the peripheral level (kidney, heart). By modulating the brain RAS, Firibastat decreases vasopressin release, decreases sympathetic nerve activity and improves baroreflex. These effects lead to a vasodilatation and an increased diuresis, thereby decreasing blood pressure.

In the brain, Firibastat causes the inhibition of aminopeptidase A (APA) which is a key enzyme in the RAS. By inhibiting APA, Firibastat decreases levels of angiotensin III in the brain, a key protein that drives vasoconstriction. It is because of these actions that take place in the brain due to Firibastat that the drug could potentially address hypertension in the population of patients that have been resistant to current treatments of hypertension that act at the peripheral level.

Quantum Genomics has concluded NEW-HOPE, which is phase 2b trial in difficult-to-treat hypertension. The trial included 256 overweight and obese patients with primary hypertension across the US including 53% of minorities patients (of whom 38% of African-American), 44% are female, and 26% are above the age of 65 years old. This kind of population is more likely to suffer from resistant hypertension.

Indeed treatment-resistant hypertension is not equally common across all demographics and ethnicities and was more prevalent in black, Hispanic, elderly and female populations. Obese patients with hypertension were 5 times more likely to be resistant to treatment.

Results of the trial indicated that treatment with Firibastat for 8 weeks resulted in significant (p<0.0001) decreased office systolic blood pressure by 9.5 mmHg (from 153.9 down to 144.4 mmHg) and was determined to be safe. Firibastat’s efficiency was similar in black (-10.5mmHg) and non-black (-8.9mmHg) populations, contrary to other anti-hypertensive classes.

The trial also showed a larger blood pressure decrease for patients with higher baseline hypertension, a predictive factor of resistant hypertension. Based on the outcome of the NEW-HOPE trial, Quantum Genomics will initiate a phase 3 pivotal trial in resistant hypertension with Firibastat.

Bron: https://ruedelabiotechnologie.wordpress ... ssion=true
Marbull liked last!

Marbull
Forum gebruiker
Forum gebruiker
Berichten: 112
Lid geworden op: 17 sep 2018 16:14
waarderingen: 15
Contacteer:

Re: Quantum Genomics

Bericht door Marbull » 05 aug 2019 00:36

Stofke liked last!
Innate Pharma, Genfit, Galapagos, Inventiva,Celyad, Quantum G, Pharnext

Stofke
Premiummember
Premiummember
Berichten: 796
Lid geworden op: 13 okt 2017 16:18
waarderingen: 445
Contacteer:

Re: Quantum Genomics

Bericht door Stofke » 18 aug 2019 19:32

Krijg foutmelding op deze link ?

Stofke
Premiummember
Premiummember
Berichten: 796
Lid geworden op: 13 okt 2017 16:18
waarderingen: 445
Contacteer:

Re: Quantum Genomics

Bericht door Stofke » 18 aug 2019 19:36

http://www.prweb.com/releases/quantum_g ... 508291.htm

Filmpje op de pagina over Firibastat

Stofke
Premiummember
Premiummember
Berichten: 796
Lid geworden op: 13 okt 2017 16:18
waarderingen: 445
Contacteer:

Re: Quantum Genomics

Bericht door Stofke » 02 sep 2019 18:57

PARIS and NEW YORK, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant arterial hypertension and heart failure, today announced that it met a new milestone of its strategic plan by receiving favourable feedback from the U.S. Food and Drug Administration (FDA) regarding the Company’s Phase III development plan and trial design for firibastat in patients with resistant arterial hypertension.

In a previously completed Phase IIb study presented at the American Heart Association (AHA) Scientific Sessions in November 2018, firibastat reached its primary endpoint and significantly lowered blood pressure to clinically relevant levels. Following these positive results, Quantum Genomics met formally with the FDA to potentially advance firibastat into two U.S. Phase III studies, one to evaluate efficacy and another to evaluate safety.

“Currently, 150 million people around the globe struggle with difficult-to-control or treatment-resistant arterial hypertension, and often times related complications,” said Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics. “The positive feedback from the FDA regarding our clinical development plan to advance firibastat into Phase III trials in the United States represents a key milestone in the execution of our strategic plan as presented in April 2018. As of today, we have diligently worked to meet these milestones that we have set forth and look forward to meeting the coming ones. The pivotal Phase III efficacy study of firibastat in difficult-to-treat or treatment-resistant arterial hypertension will thus start by the end of 2019 and its results will be available in the second half of 2021.”

The Company’s efficacy study, QGC001/3QG1, will be a three-month double-blind, placebo-controlled study assessing the efficacy of firibastat to reduce hypertension in patients with difficult-to-treat or resistant hypertension. QGC001/3QG1 is expected to enroll 500 hypertensive patients with systolic automated office blood pressure (AOBP) above 140 mmHg despite being treated with two (difficult-to-treat) or three anti-antihypertensive classes including a diuretic (resistant). Patients will receive firibastat or placebo on top of their current treatment. The primary endpoint will be change from baseline in systolic AOBP.

The Company’s safety study, QGC001/3QG2, will be an open label study assessing the long-term safety of firibastat. QGC001/3QG2 is expected to enroll 750 difficult-to-treat or resistant hypertensive patients with systolic AOBP above 140 mmHg. 650 patients will receive firibastat for six months, and 100 patients will receive firibastat for one year.

Stofke
Premiummember
Premiummember
Berichten: 796
Lid geworden op: 13 okt 2017 16:18
waarderingen: 445
Contacteer:

Re: Quantum Genomics

Bericht door Stofke » 11 sep 2019 20:15

Paris & New York, September 11, 2019

Quantum Genomics Launches Study of Firibastat in Patients with Renal Failure

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that a directly targets the brain to treat resistant hypertension and heart failure, today announced that it is launching an additional study with firibastat, a first-in-class brain aminopeptidase A inhibitor (BAPAI), in patients with renal failure. The enrollment of the first patient in the study is expected in September 2019 and the results of the study are expected in April 2020.
“The analysis of NEW-HOPE, Quantum Genomics’ Phase IIb study of firibastat in hypertension, has demonstrated that firibastat does not negatively impact renal function. This study aims to confirm that firibastat could potentially be used to treat hypertension, in particular, treatment-resistant hypertension or heart failure, even in the case of associated renal failure," said Bruno Besse, M.D., Chief Medical Officer of Quantum Genomics. A drug that can be used even in the case of associated renal failure represents a real benefit for managing hypertensive patients or those with heart failure. If the results of this study are positive, the market for firibastat would be considerably expanded.
Renal failure represents a serious and common comorbidity in patients with hypertension, especially in those with resistant hypertension or heart failure, that can often complicate the treatment of high blood pressure. Most of the current treatment options (ACE inhibitors, sartans, diuretics) in these two pathologies present challenges in the case of associated renal failure, and some are contraindicated, such as specific diuretics and spironolactone.
Firibastat is very weakly eliminated by the kidneys and as a consequence has not resulted in any decline in renal function in subjects treated in the clinical studies conducted so far.
The study (QGC001/1QG4) will examine the safety and tolerance of firibastat in patients with renal failure. The objective of this study, which will cost less than €500K, is to compare the pharmacokinetics and tolerance of a single 500-mg dose of firibastat in 14 healthy volunteers versus 14 patients with severe renal failure. The study will take place at four sites in France and Hungary. All regulatory authorizations have been obtained.

Upcoming events in the coming months
October 3, 6:00 PM: publication of the results for the first half-year of 2019
October 16: company shareholders club evening (date likely to be changed according to events) November 11-13: Bio Europe in Hamburg
November 16-18: American Heart Association (AHA) Congress in Philadelphia
November 20 -21: Jefferies Conference in London
January 13-16, 2020: JP Morgan/Biotech Showcase Conference in San Francisco

Stofke
Premiummember
Premiummember
Berichten: 796
Lid geworden op: 13 okt 2017 16:18
waarderingen: 445
Contacteer:

Re: Quantum Genomics

Bericht door Stofke » 13 sep 2019 22:13

Quantum Genomics / Point on file: The course of action is framed, why and for what purpose?

  ruedelabiotechnologie
7 hours ago
Advertising

Paris: 14h53 / Bombay 18h23 Friday 13 September 2019



Is the course of action framed, why and for what purpose?

On Wednesday, September 11, 2019, we watched closely the behavior of the title.

About twenty ATP purchase orders were systematically followed by a sell order.

All the latest positive announcements have been systematically sold.

Why and for what purpose?

We also observed on Twitter, on some stock market forums, a smear campaign of the company. A website even called on its subscribers to openly sell 50% of their positions, without knowing the file, without knowing the financial visibility of the company, this same site going up to publish several negative articles in the same week, ignoring the last advanced and the latest press release. This same site which advised to sell the title at 4 € just before is climbing to 7.55 €!

What is the purpose of pursuing a file if it is not to know that its potential is important?

Apparently many investors follow the record very closely and hope to return to the title at lower costs.

A little reminder that it is important to remind critics of the title.

Quantum Genomics has been awarded the 2017 Galien MedStartUp Award for Best Innovative Clinical Study Design. Quantum Genomics has achieved excellent phase 2b NEW-HOPE results in high blood pressure and these results have been published in the most prestigious scientific journals in the world including 'Circulation' which is a reference in cardiovascular diseases. Quantum Genomics has launched a phase 2b in heart failure. The Paris biotech published in June, excellent results of a single-dose drug in high blood pressure. The biopharmaceutical company has been awarded the European Rising Tech label, which includes the most promising technology stocks on the Euronext markets. Last week Quantum Genomics announced that it had received a positive feedback from the FDA on the development plan and phase III protocols of firibastat in patients with resistant hypertension and Wednesday the Parisian biotech announced to launch a study with firibastat in patients with kidney failure, in case of positive results of this study, the market of firibastat would be considerably expanded.

Unlike many biotechs, the positive progress succeeds and often even ahead of schedule, the company's strategic plan is followed to the letter, and Jean-Philippe Milon the CEO confirms "to date, we have scrupulously respected all the steps and we will respect those to come ".

The next step may well be the announcement of the long-awaited partnership by the shareholders. It took Switzerland Idorsia biotech a little over 6 months to sign a $ 230 million partnership with Janssen, a subsidiary of Johnson & Johnson. As a reminder, the results of Quantum Genomics studies are superior to those of Idorsia.

It's now nine months since Quantum Genomics announced excellent phase 2b NEW-HOPE results in high blood pressure. Compared to Idorsia which weighs 3.3 billion euros, it makes sense that Quantum Genomics negotiations take a longer time.

During the evening shareholder, Jean-Philippe Milon explained that a partnership is signed only once, once. The exercise is therefore to sign the best possible partnership for the benefit of patients and shareholders. The ultimate goal is to market a drug as quickly as possible to save lives.

As a reminder, the prestigious financial analyst EDISON values ​​Quantum Genomics at 860 million euros against 80 million euros today.

For 2019, 4 financial analysts cover Quantum Genomics, EDISON with the purchase with a TP at € 52 43, AURGALYS strong purchase with a Target Price at € 16.47, Gilbert Dupont with the purchase with a TP at € 16.80 , and Invest Securities with the purchase at 9 €. Two other analysts are expected to cover the company soon.

The title Quantum Genomics is capable of stock market exploits. Between October and December 2018 its rise was about + 300%.

To summarize, the Parisian biotech could soon create a surprise. The fundamentals are unique and revolutionary, the schedule is respected, the results of studies are excellent, the financial analysts to the purchase, the direction is serene.
The results of the pivotal phase III efficacy study will be available in the second half of 2021. The goal is always the same, go fast to save lives. In the event of positive results, a multi-billion dollar market will open up for Quantum Genomics.

On October 16, 2019, Jean-Philippe Milon and his management team will receive the shareholders during the evening of the club of the shareholders of the company (date likely to be modified according to the events).

Newsfow coming soon:

- Signature of a partnership with a first-rate pharmaceutical company.

- Launch of phase III in arterial hypertension with Firibastat.

- Coverage of the title of new US and European financial analysts.

- Update financial analysts already covering the title.

- Phase 2b advances in heart failure.

- Results of the study with firibastat in patients with renal failure (April 2020).
Marbull liked last!

Stofke
Premiummember
Premiummember
Berichten: 796
Lid geworden op: 13 okt 2017 16:18
waarderingen: 445
Contacteer:

Re: Quantum Genomics

Bericht door Stofke » 22 sep 2019 21:21

Nog een leuk artikel van 19 juni. Vol spanning wachten...

https://ruedelabiotechnologie.wordpress ... -genomics/

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. 
Registreer binnen enkele tellen



Plaats reactie